Answers are grounded in this paper and cite their sources.
CHRONIC spontaneous urticaria (CSU) was a key focus at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, reflecting a growing momentum in the search for better treatments.1 This unpredictable skin condition, marked by wheals, itching, and angioedema, continues to significantly impact patients’ quality of life (QoL). Despite available therapies, CSU remains poorly controlled for many individuals, highlighting an unmet need for more effective, lasting solutions. At the EAACI Congress, new data on emerging therapies such as barzolvolimab, briquilimab, and remibrutinib generated interest for their novel mechanisms and potential for long-term disease control.
No takes yet. Share an insight, caveat, or question.
Smiley et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: